Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorLeeds Beckett University

About this trial

This 12-week, double-blind, placebo-controlled trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight adults aged 18 to 40 with impaired glucose tolerance, a preclinical condition where blood glucose regulation is mildly disrupted. Seventy participants will be randomly assigned to receive either Lab4P or a placebo. The study will assess changes in memory, executive function, and processing speed, along with blood glucose control, cardiovascular function, cholesterol levels, body composition, and markers of inflammation. The study will also analyse changes in the gut microbiome and evaluate the safety and tolerability of the probiotic.

Eligibility criteria

Qualifiers

Aged 18-40 years

Body Mass Index (BMI) between 25.0 and 29.9 kg/m² (classified as overweight)

In good general health (self-reported)

Normal self-reported sleep patterns, with no history of diagnosed sleep disorders

Disqualifiers

Diagnosed diabetes (any type).

Diagnosed sleep disorders.

Fasting glucose >6.9 mmol/L during screening.

History of bariatric surgery (e.g., gastric bypass, sleeve gastrectomy).

Trial design

Treatments tested in this trial

  • Lab4p Probiotic Consortium
  • Placebo

Treatment groups

70 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Leeds Beckett University

Lead sponsor

Cultech Ltd, Port Talbot, UK

Collaborator